Researchers at Chengdu Brilliant Pharmaceutical Co. Ltd. and Scinnohub Pharmaceutical Co. Ltd. have disclosed 15-hydroxyprostaglandin dehydrogenase inhibitors reported to be useful for the treatment of diabetes, osteoporosis and more.
Scinnohub Pharmaceutical Co. Ltd. has divulged cyclin-dependent kinase (CDK) inhibitors, particularly CDK9 inhibitors, reported to be useful for the treatment of cancer.
Scinnohub Pharmaceutical Co. Ltd. has patented new 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitors reported to be useful for the treatment of autoimmune diseases, fibrosis, ulcerative colitis and more.
Scinnohub Pharmaceutical Co. Ltd. has identified S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.
Scinnohub Pharmaceutical Co. Ltd. has synthesized S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.